Cite
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
MLA
Eggermont, Alexander M. M., et al. “Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.” The New England Journal of Medicine, vol. 375, no. 19, Nov. 2016, pp. 1845–55. EBSCOhost, https://doi.org/10.1056/NEJMoa1611299.
APA
Eggermont, A. M. M., Chiarion-Sileni, V., Grob, J.-J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., Lebbé, C., Ferraresi, V., Smylie, M., Weber, J. S., Maio, M., Bastholt, L., Mortier, L., Thomas, L., Tahir, S., … Testori, A. (2016). Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. The New England Journal of Medicine, 375(19), 1845–1855. https://doi.org/10.1056/NEJMoa1611299
Chicago
Eggermont, Alexander M M, Vanna Chiarion-Sileni, Jean-Jacques Grob, Reinhard Dummer, Jedd D Wolchok, Henrik Schmidt, Omid Hamid, et al. 2016. “Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.” The New England Journal of Medicine 375 (19): 1845–55. doi:10.1056/NEJMoa1611299.